Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07527936) titled 'A Study of BEN301 Injection in theTreatment of Autoimmune Diseases' on April 7.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: RenJi Hospital
Condition:
Systemic Sclerosis (SSc)
Rheumatoid Arthritis (RA)
Sjogren's Syndrome (SS)
Idiopathic Inflammatory Myopathies(IIM)
Intervention:
Biological: Single administration of 1x10^8 viable CD4+ CAR+ Foxp3+ cells.
Recruitment Status: Not recruiting
Phase: Early Phase 1
Date of First Enrollment: April 20, 2026
Target Sample Size: ...